Zenas BioPharma (ZBIO) Operating Expenses (2023 - 2026)

Zenas BioPharma's Operating Expenses history runs 4 years deep, the most recent figure standing at $77.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 63.43% year-over-year to $77.4 million in Q1 2026; TTM through Mar 2026 was $423.1 million, a 124.28% increase from a year earlier, with the FY2025 full-year figure at $393.1 million, up 132.73% from the prior year.
• Operating Expenses retreated to $77.4 million in Q1 2026 per ZBIO's latest filing, from $238.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $238.0 million in Q4 2025 and bottomed at $14.4 million in Q3 2023.
• The 4-year median for Operating Expenses is $47.3 million (2025), against an average of $61.7 million.
• Biggest YoY gain for Operating Expenses was 292.56% in 2025; the steepest drop was 28.29% in 2025.
• Year by year, Operating Expenses stood at $24.8 million in 2023, then surged by 144.65% to $60.6 million in 2024, then jumped by 292.56% to $238.0 million in 2025, then plunged by 67.5% to $77.4 million in 2026.
• Per Business Quant, the three latest ZBIO Operating Expenses figures stand at $77.4 million (Q1 2026), $238.0 million (Q4 2025), and $52.6 million (Q3 2025).